drugset / Trial / NCT02205762
LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis
Phase 2/3
Active not recruiting
1400 enrolled
North American Consortium for Histiocytosis
Histiocyte Society · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The LCH-IV is an international, multicenter, prospective clinical study for pediatric Langerhans Cell Histiocytosis LCH (age \< 18 years).
Timeline
- Start
- 2016-11-02
- Primary completion
- 2026-07
- Completion
- 2026-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 2-chlorodeoxyadenosine | Small molecule | — | — |
| Subject | Cytarabine | Small molecule | — | — |
| Subject | Indomethacin | Small molecule | — | Oral |
| Subject | MERCAPTOPURINE ANHYDROUS | Small molecule | — | — |
| Subject | Methotrexate | Small molecule | — | Oral |
| Background | Intravenous immunoglobulin | Protein / enzyme biologic | — | Intravenous |
| Background | Prednisone | Other / unclassified | — | — |
| Background | Vinblastine | Small molecule | — | — |